Who
Douglas Forsyth
Director
Company insider
Files Form 4 as: Director, Inhibrx Biosciences; Director, Inhibrx; Other, Virtus Equity & Convertible Income Fund; Other, Virtus Convertible & Income Fund.
In numbers
- Trades disclosed
- 87
- Buys
- 8
- Sells
- 2
- Bought
- $2.2M
- Sold
- $652K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 15 Aug 2007
- Last trade
- 8 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $287K2,500 at $114.65 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $287K2,500 at $114.65 | filing |
| 3 Jun 2026filed 18 Sep 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 18 Sep 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 28 May 2025filed 29 May 2025 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 23 Aug 2024filed 26 Aug 2024 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $842K59,812 at $14.07 | filing |
| 22 Aug 2024filed 26 Aug 2024 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $196K15,188 at $12.89 | filing |
| 30 May 2024filed 30 May 2024 | INBX Inhibrx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 30 May 2024filed 30 May 2024 | Inhibrxoption or derivative | SEC FORM 4 Code D | —17,259 | filing |
| 30 May 2024filed 30 May 2024 | Inhibrxoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 30 May 2024filed 30 May 2024 | Inhibrxoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 30 May 2024filed 30 May 2024 | Inhibrxoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 30 May 2024filed 30 May 2024 | Inhibrx | SEC FORM 4 Code D | $17.9M598,257 at $30.00 | filing |
| 29 May 2024filed 30 May 2024 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Code A | —149,564 | filing |
| 25 May 2023filed 30 May 2023 | Inhibrxoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 May 2022filed 26 May 2022 | Inhibrxoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 7 Jun 2021filed 8 Jun 2021 | Inhibrxoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 21 Aug 2020filed 21 Aug 2020 | Inhibrxoption or derivative | SEC FORM 4 Code C | —143,266 at $0.00 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK)INBX · themarketsdaily.com · 25 Oct 2026Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)INBX · tickerreport.com · 23 Oct 2026Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) CEO Acquires $848,982.40 in StockINBX · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Douglas Forsyth; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.